Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation’s most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
One of the biggest obstacles to treating pleural mesothelioma cancer effectively is its often late-stage diagnosis. A recent study shows encouraging signs that those days could be ending.
Novel diagnostic testing using blood serum and infrared spectroscopy is being explored to better characterize and differentiate mesothelioma in its early stages from other lung diseases and benign effusions.
The study is being conducted by scientists and doctors in Ankara and Istanbul, Turkey, spread through various hospitals and university medical centers within the region. Biochimica et Biophysica Acta – Molecular Basis of Disease will publish the study in October 2022. Science Direct released an online version June 23.
“As the symptoms of mesothelioma usually take decades to become noticeable, timing is the worst aspect of this disease,” co-author Dr. Feride Severcan, Altinbas University Faculty of Medicine, told The Mesothelioma Center at Asbestos.com. “An early diagnosis from easily collected blood serum is a very valuable approach, increasing the chance of successful treatment and survival rate.”
Because of mesothelioma’s typical late-stage diagnosis, less than 25% of pleural mesothelioma patients even qualify for aggressive surgery and the most effective multimodality treatment.
The majority of patients diagnosed with pleural mesothelioma receive only standard chemotherapy and have a median survival of 12 months. Most are not diagnosed for at least 30 years after first being exposed to toxic asbestos fibers, the primary cause of the disease.
Mesothelioma is a rare cancer that is diagnosed in an estimated 3,000 people annually in the U.S. Dry cough, slight shortness of breath, fatigue, muscle weakness, hoarseness and difficulty swallowing are common early symptoms of mesothelioma, but these are also similar to signs of other benign or malignant diseases. The average age at diagnosis is 74.
A mesothelioma diagnosis is often a drawn-out process that usually starts with imaging studies, including chest X-rays, CT, MRI and PET scans. It eventually moves to more invasive surgical procedures such as a thoracentesis to obtain a biopsy sample and a thoracoscopy for a pleural tissue biopsy.
“It would be critical to find new diagnostic approaches, which are accurate, preferably noninvasive, rapid, low-cost, operator independent and able to create reliable information,” Severcan said. “An early and accurate diagnosis of MPM [malignant pleural mesothelioma] is essential to decreasing the morbidity rate.”
The study started with blood serum samples, regardless of pleural fluid status, which typically doesn’t occur until the later stages of disease. The tool being used is called an attenuated total reflectance-Fourier transform infrared spectroscopy, or ATR-FTIR, that can help analyze even small amounts of blood serum.
Samples were obtained from 25 patients with malignant mesothelioma, 31 with lung cancer, 26 with nonmalignant pleural effusions and 30 healthy individuals to serve as a control group. The aim was to differentiate between lung cancer, benign effusions, healthy tissue and mesothelioma through various biomarkers.
For the four different groups, a linear discriminant analysis was obtained with an 87.5% accuracy rating, showing promising potential.
The results demonstrated the biomolecular composition and structural differences between the four groups of serum samples.
“Based on FTIR measurements, the molecular fingerprints of serum samples can be obtained and the structural and compositional changes in the components of that fluid can serve as biomarkers for early signs of the disease,” Severcan said.
Essentially, the testing could result in an early diagnosis of mesothelioma prior to obvious symptoms. It could be done easily for high-risk, asbestos-exposed populations. The noninvasive approach would likely be welcomed by anyone who had a history of exposure.
If utilized, the approach could help identify the disease and start the mesothelioma treatment process sooner, when success is more likely.
“An early diagnosis from easily collected blood serum is a very valuable approach,” the authors concluded. “In the absence of reliable noninvasive diagnostic tests today, there is a critical need. Our study can be a guide for future studies.”
Povtak, T. (2022, August 22). Blood Serum Diagnostic Test for Mesothelioma Explored in Study. Asbestos.com. Retrieved August 24, 2022, from https://www.asbestos.com/news/2022/08/22/blood-serum-mesothelioma-diagnosis/
Povtak, Tim. “Blood Serum Diagnostic Test for Mesothelioma Explored in Study.” Asbestos.com, 22 Aug 2022, https://www.asbestos.com/news/2022/08/22/blood-serum-mesothelioma-diagnosis/.
Povtak, Tim. “Blood Serum Diagnostic Test for Mesothelioma Explored in Study.” Asbestos.com. Last modified August 22, 2022. https://www.asbestos.com/news/2022/08/22/blood-serum-mesothelioma-diagnosis/.
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Stay up-to-date on treatment, research, clinical trials, doctors and survivors
Mesothelioma Center – Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.
The information on this website is proprietary and protected. It is not a substitute for professional medical advice, diagnosis or treatment. Any unauthorized or illegal use, copying or dissemination will be prosecuted. Please read our privacy policy and disclaimer for more information about our website.
Asbestos.com is sponsored by law firms. This website and its content may be deemed attorney advertising. Prior results do not predict a similar outcome. For more information, visit our sponsors page.
This site complies with the HONcode standard for trustworthy health information: Verify Here.
Our free mesothelioma treatment guide contains a list of top doctors and active mesothelioma clinical trials. Get information tailored to your unique diagnosis, and learn about our free services.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592